Conference Track

Prostate Cancer

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Gleason Grade Predicts Survival in Prostate Cancer Patients not Undergoing Therapy
Radiation Therapy Decreases Risk of Prostate Cancer Progression After Radical Prostatectomy
PSA Measures Predict Time to Bone Metastasis and Survival in Prostate Cancer Patients With Rising PSA Despite Androgen Deprivation
High-Dose Calcitriol May Prolong Survival in Androgen-Independent Prostate Cancer
Nomogram Identifies Prostate Cancer Patient Risk for Metastatic Progression Following Radical Prostatectomy
Model Defined to Identify Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy
PSA Doubling Time and Biopsy Gleason Score Predict Risk for Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Radiation Therapy
PSA Response a Poor Surrogate Endpoint for Overall Survival in Trials of Metastatic Hormone-Refractory Prostate Cancer
Atrasentan May Have Clinical Benefit in Metastatic Hormone-Refractory Prostate Cancer
Intermittent Weekly Docetaxel Plus Estramustine Effective and Well Tolerated in Hormone-Refractory Prostate Cancer
Comprehensive Health Screening May Be More Appropriate Than PSA Screening Alone to Identify African-American Men at High Risk of CVD and Prostate Cancer
Carbon Ion Radiotherapy Achieves Favorable Survival Outcome With Low Incidence of Normal Tissue Damage in Previously Untreated Patients With Prostate Cancer
Classified Prostate-Specific Antigen Half-Time and Area Under the Curve Corrected During Chemotherapy Are Prognostic Factors for Overall Survival in Patients with Hormone-Refractory Prostate Cancer
Docetaxel/Estramustine Active and Well Tolerated in Elderly Men With Hormone-Refractory Prostate Cancer

Expert Analysis

Prostate Cancer

Program Director:
Roy A. Beveridge, MD

Faculty:
Derek Raghavan, MD, PhD Nicholas J. Vogelzang, MD E. David Crawford, MD
David I. Quinn, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the results of recent studies of treatment strategies for hormone-refractory prostate cancer
Discuss new data on the natural history of prostate cancer and on screening among American-American men
Review new insights into the management of patients following radical prostatectomy

Earn CME credit by reading the expert analysis and commentary on prostate cancer. Topics covered include:

Docetaxel-Containing Regimens in Hormone-Refractory Prostate Cancer
Atrasentan in Metastatic Hormone-Refractory Prostate Cancer
Prostate Cancer: Natural History in Untreated Patients
Metastatic Risk and Impact of Neoadjuvant Therapy
Rising PSA After Radical Prostatectomy
Carbon Ion Radiation Therapy
Adjuvant Therapy Following Radical Prostatectomy
Screening in High-Risk African American Patients
Honorable Mention: Other ASCO Abstracts of Interest

CME CREDIT INFORMATION

Release Date: 07/27/05

Expiration Date: 07/26/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.